Visceral leishmaniasis (VL) is one of the major infectious diseases affecting the poorest
regions of the world. Current therapy is not very much satisfactory. The alarming rise of drug …

The first completed genome project of any living organism, excluding viruses, was of the
gammaproteobacteria Haemophilus influenzae in 1995. Until the last decade, genome …

This review describes the worldwide situation of visceral and tegumentary leishmaniasis
with an emphasis on diagnosis, including methods for the detection of antibodies, antigens …

The completion of the genomic sequences of many protozoan pathogens of humans,
including species of Leishmania, Trypanosoma and Plasmodium, provide new approaches …

This article reviews the recent advances made in the field of human leishmaniasis. Special
emphasis is placed upon the application of various molecular tools for accurate and rapid …

Visceral leishmaniasis (VL) can be lethal if untreated; however, the majority of human
infections with the etiological agents are asymptomatic. Using Illumina Bead Chip …

Until recently, chemotherapy for visceral leishmaniasis (VL; also known as kala-azar) was
severely limited by factors such as high cost, route of administration, generation of side …

Leishmania donovani causes visceral disease (kala-azar), a major health problem
throughout the tropics with 500 000 new cases every year. Leishmania differentiates from …

Visceral leishmaniasis (VL), a deadly parasitic disease, is a major public health concern
globally. Countries affected by VL have signed the London Declaration on Neglected …

Leishmania braziliensis infection frequently results in cutaneous leishmaniasis (CL). An
increase in incidence of drug-resistant CL leading to treatment failure has been reported …